Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
about
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementSunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignanciesDual modulation of MCL-1 and mTOR determines the response to sunitinib.Sunitinib toxicity management - a practical approach.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Sunitinib malate for the treatment of renal cell carcinoma.Drug interactions with sunitinib.Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.Safety of available treatment options for renal cell carcinoma.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanomaSunitinib side effects as surrogate biomarkers of efficacy.Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.[Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.The use of sunitinib in renal cell carcinoma: where are we now?[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].
P2860
Q26801279-3D6A537F-532C-49F7-B70D-89E0D40773E1Q33404547-0BBE6B77-98CA-478B-925E-3500080D4A46Q33418378-2B680090-B707-4CEE-910F-AD8C747B3941Q33432282-A0506E83-E98F-4F5C-8F3F-92D62FF3C46FQ35504499-15ABC006-8F18-4C76-BC2F-1F817AFA1A0EQ35742534-52BDBD51-4591-47C5-B9C7-E5448B8068D7Q37117596-2371FB38-C905-4BA2-9918-3575DF498BCEQ37142970-C781EA04-F3BC-46D9-9F2C-D353495325A9Q37544978-3123F81C-9FDF-44CF-938E-4E1D03832470Q37560644-60C61CA3-6FDB-4583-B4A7-4346246C2104Q38004605-80633495-A5B3-4F07-8E5B-88275809D14DQ38011201-C370D8A5-F4D6-4E9C-84BC-17E46CD3F0F9Q38176853-707A8B4E-BFE7-406B-9BCE-46EAF6C20586Q38540687-19A41E60-E33A-4936-8BAC-818783B435C1Q38664221-4564842E-8E39-4D58-8508-F56381086366Q38667743-E45B7CC7-63C4-4751-9A3B-5427ACE54494Q38824719-BA87BDA8-1B85-43F0-A245-9C429960D408Q38948950-6BF02CC0-C7D3-4BAA-B96C-7FC45DBBDA84Q38981033-0CDEABAA-40A6-4CD4-B22A-DB7D2CB18AD3Q39092937-81CF6E5B-9488-4777-BA89-C12333ED57E6Q39172001-12A44873-ECCC-452B-8665-EC11EFE31684Q44020739-885E58A2-68B8-4BF3-A269-0454FE607285Q45160761-D56765E9-C37F-4946-B898-46C80D7CEC56Q45329617-537187D3-CA16-49F5-AF14-7C6C581511EEQ48634468-E280BD7E-B3AE-40CE-9332-B6D1823DF561Q53113774-CFA399B6-F2E5-4CD5-98A2-F515DE2B0B1CQ54196218-6071A9E8-0D10-4611-ACE6-97F5B7B455FC
P2860
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@ast
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@en
type
label
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@ast
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@en
prefLabel
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@ast
Sunitinib in metastatic renal ...... noncardiovascular toxicities.
@en
P2093
P2860
P1433
P1476
Sunitinib in metastatic renal ...... f noncardiovascular toxicities
@en
P2093
Amy Potter
Christian Kollmannsberger
Eric Raymond
Jerome Hershman
Laura Wood
Mellar Davis
Nancy Dawson
Nathaniel Treister
Patricia Creel
Patrick Burnett
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0263
P577
2011-04-13T00:00:00Z